MASLD/MASH Learning Center
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
September 2025
The reclassification of nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) marks a significant shift in understanding liver disease, particularly in Saudi Arabia, where metabolic disorders are highly prevalent. This study aimed to develop expert consensus recommendations for early detection, specialist referral, and management of MASLD/metabolic dysfunction-associated steatohepatitis (MASH) in Saudi Arabia. A modified Delphi process was...
Read More
Diagnostic and Clinical Implications of High Spleen-To-Liver Stiffness Ratio in MASH-A Prospective, Comparative Study
August 2025
CONCLUSIONS: This study demonstrates that SSM/LSM ratios vary across different liver disease aetiologies. Since MASH patients-after adjusting for liver disease severity-show higher SSM/LSM ratios and larger spleen diameters than ALD, our results support the concept of a presinusoidal component of PH in MASH patients.
Read More
Steatohepatitis alters lymphocytes cytotoxicity and localization, accelerating colorectal liver metastases
August 2025
CONCLUSIONS: This research underscores the crucial influence of diet-induced immune changes on CRLM establishment and progression. It illustrates that the co-localization of immune cells within liver metastases significantly affects their functionality, highlighting potential therapeutic strategies to balance immune exhaustion and activation.
Read More
Mitochondrial dysfunction in hepatocellular carcinoma: from metabolism to targeted therapies
August 2025
Globally, liver cancer is reported to be the third leading cause of cancer-related mortality. The most common type of these cancers is hepatocellular carcinoma (HCC). Current preventive strategies, including lifestyle modifications, antiviral therapies, and surveillance, are limited in their effectiveness. Mitochondria play critical roles in regulating cellular metabolism, oxidative stress, and apoptosis. Mitochondrial dysfunction can accelerate HCC progression, particularly in patients with...
Read More
Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis
August 2025
Immune cells play a central yet poorly understood role in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASLD/MASH), a global cause of liver disease with limited treatment. Limited access to human livers and lack of studies across MASLD/MASH stages thwart identification of stage-specific immunological targets. Here we provide a unique single-cell RNA sequencing atlas of paired peripheral blood and liver fine-needle aspirates from a...
Read More
Disparities in liver transplantation for metabolic dysfunction-associated steatohepatitis-associated hepatocellular carcinoma
August 2025
CONCLUSION: Hispanic patients are less likely to undergo LT for MASH-HCC, concerning given their susceptibility to MASH and HCC. There were very few NH Black candidates. Disparities were also unequal across regions, which is particularly concerning in states where at-risk populations have rising cancer incidence. Additional research is needed to identify strategies for mitigating these differences in access to LT for MASH-HCC.
Read More
Semaglutide in the treatment of metabolic dysfunction-associated steatohepatitis (MASH)-a turning point?
August 2025
No abstract
Read More
Adipocyte-specific deletion of gp130 prevents ketogenic diet-induced hepatic steatosis
August 2025
CONCLUSIONS: Our studies demonstrate the importance of adipose tissue-liver crosstalk in mediating MASLD progression and identify adipocyte IL-6-gp130 as a potential therapeutic target.
Read More
UPLC-MS/MS Metabolomics Reveals Babao Dan's Mechanisms in MASH Treatment with Integrating Network Pharmacology and Molecular Docking
August 2025
Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive disease that easily develops into cirrhosis and hepatocellular carcinoma, but its pathogenesis is not clear, and most therapeutic drugs have obvious limitations. However, Babao Dan (BBD) has a good therapeutic effect on liver disease, but its treatment mechanism is still to be studied. Therefore, we further investigated the mechanism of BBD in treating MASH. Methods: We predicted BBD-related targets through...
Read More
Therapeutic Potential of Probiotics in Metabolic Dysfunction-Associated Steatohepatitis: A Comprehensive Review
August 2025
Metabolic dysfunction-associated steatohepatitis (MASH) constitutes a significant and progressive liver disease, characterized by a complex pathogenesis that involves dysbiosis of the gut microbiota. While the multifaceted nature of MASH is widely recognized, its underlying mechanisms remain the subject of active investigation. Contemporary research highlights the critical role of the gut-liver axis, suggesting that disturbances in the gut microbiome may contribute to the progression of the...
Read More
Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention
August 2025
Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly increases the risk of steatohepatitis and cirrhosis and multiple extrahepatic complications, in particular, cardiometabolic disease, including type 2 diabetes, atherosclerotic cardiovascular disease (CVD), and heart failure, with a significant negative impact on health-related quality of life, becoming a substantial economic burden. Moreover, cardiovascular events represent the leading cause of death in MASLD...
Read More
Liver Sinusoidal Endothelial Cells and Their Regulation of Immunology, Collagenization, and Bioreactivity in Fatty Liver: A Narrative Review
August 2025
Liver sinusoidal endothelial cells (LSECs) are essential for preserving liver homeostasis. Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a category of hepatic disorders characterized by excessive fat accumulation in the liver, known as steatosis. Over time, accumulated hepatic fat can induce inflammation of the liver (hepatitis). MASLD is among the most prevalent types of chronic liver disease. Obesity and Type 2 diabetes mellitus (T2DM) are frequent etiological...
Read More